Unknown PHASE1 INTERVENTIONAL 3-arm NCT04599556

Clinical Trial for the Safety and Efficacy of Anti-CD7 CAR-T Cell Therapy for Patients With Relapsed or Refractory CD7 Positive Hematological Malignancy

Clinical Trial for the Safety and Efficacy of Anti-CD7 Chimeric Antigen Receptor Cell Therapy for Patients With Relapsed or Refractory CD7 Positive Hematological Malignancy

Sponsor: Yake Biotechnology Ltd.

Conditions CD7+ Acute Leukemia CD7+ Lymphoma

Interventions anti-CD7 CAR-T

Updated 8 times since 2020 Last updated: Nov 29, 2023 Started: Apr 1, 2021 Primary completion: Dec 30, 2023 Completion: Dec 30, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on CD7+ Acute Leukemia and CD7+ Lymphoma, this trial is ongoing. The trial is conducted by Yake Biotechnology Ltd. and has accumulated 8 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

8 versions recorded

Jan 2026 — Present [monthly]

Unknown PHASE1

Status: Recruiting → Unknown
Sep 2024 — Jan 2026 [monthly]

Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1
Jan 2024 — Jul 2024 [monthly]

Recruiting PHASE1

Phase: PHASE1_PHASE2 → PHASE1
Sep 2022 — Jan 2024 [monthly]

Recruiting PHASE1_PHASE2

▶ Show 3 earlier versions

Nov 2021 — Sep 2022 [monthly]

Recruiting PHASE1_PHASE2
Jan 2021 — Nov 2021 [monthly]

Recruiting PHASE1_PHASE2
Nov 2020 — Jan 2021 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Yake Biotechnology Ltd.
Zhejiang University

Data source: Zhejiang University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Hangzhou, China